Accuracy of endoanal ultrasound in the follow-up assessment for squamous cell carcinoma of the anal canal treated with radiochemotherapy

2008 ◽  
Vol 23 (5) ◽  
pp. 1054-1057 ◽  
Author(s):  
Jacopo Martellucci ◽  
Gabriele Naldini ◽  
Caterina Colosimo ◽  
Luca Cionini ◽  
Mauro Rossi
Keyword(s):  
Squamous Cell Carcinoma ◽  
Anal Canal ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Endoanal Ultrasound

ANAL CANAL SQUAMOUS CELL CARCINOMA TREATED WTH INTENSITY MODULATED RADIATION THERAPY BASED CONCURRENT CHEMORADIATION–RETROSPECTIVE ANALYSIS OF CLINICAL OUTCOME AND TOXICITIES

2021 ◽  
pp. 42-48
Author(s):  
Geethi M H ◽  
C D Sivanandan ◽  
Sajeed A ◽  
Roshni S ◽  
Arun Sanker S ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Clinical Outcome ◽  
Anal Canal ◽  
Cell Carcinoma ◽  
Retrospective Analysis ◽  
Squamous Cell ◽  
Treatment Time ◽  
Free Survival ◽  
Intensity Modulated

Purpose: This retrospective analysis is aimed to report the single institution experience from an Asian country utilizing Intensity Modulated Radiotherapy (IMRT) based Chemo radiation in Anal Canal Squamous Cell Carcinoma (ASCC) with an emphasis on efcacy, toxicity and disease and treatment-related variables associated with outcomes. Study was conduc Materials And Methods: ted in the department of Radiation Oncology at Regional Cancer Center, Thiruvananthapuram. All Patients with biopsy proven ASCC diagnosed between January 2014 and December 2018 and receiving curative intent IMRT were identied and follow up data till December 2020 was collected. Primary end point was Disease-free survival (DFS). Secondary end points were Overall Survival (OS), Colostomy-free survival (CFS) Loco regional Failure (LRF) and Toxicities. A total of 34 patients were analyzed during a median follow up of Results: 34 months. Twenty ve patients (73.5%) were in stage IIIB. Median overall treatment time was 36 days. The estimated two year DFS, OS and CFS were 79.4 %, 93.9 %and 97% respectively. Disease recurrence at any point on follow up occurred in ve patients (14.7%). Primary Tumor size of more than or equal to 5 cm and development of grade three anemia during RT was associated with inferior DFS in Univariate analysis. Patients taken less than two cycles of chemotherapy, there was a trend for inferior OS. Acute grade 3 or more dermatological toxicities was 44% and hematological toxicity was 35.3%. Radiotherapy break occurred in 38.2%of patients with a median of 5.5 days (range 2-13). Of the available patients chronic toxicities were reported for 40% and were of grade 2. IMRT is associated with favorable toxicity rates and excellent Conclusion: long-term efcacy in Asian population also where patients are presenting in an advanced stage. Reducing the total treatment time by SIB technique may improve the clinical outcome.

Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15001-e15001
Author(s):  
Evan Carl White ◽  
Kelly Erickson ◽  
Alex Aleshin ◽  
Winston Wei Lien ◽  
Aroor R. Rao
Keyword(s):  
Squamous Cell Carcinoma ◽  
Anal Canal ◽  
Cell Carcinoma ◽  
Mitomycin C ◽  
Squamous Cell ◽  
Randomized Clinical Trials ◽  
Proportional Hazards ◽  
Concurrent Chemotherapy ◽  
Cox Proportional Hazards

e15001 Background: Concurrent chemoradiotherapy (CRT) with 5-fluorouracil (5-FU) and mitomycin-C (MMC) is standard treatment for squamous cell carcinoma of the anal canal. Randomized clinical trials in Europe have used 1 cycle MMC, while American studies use 2 cycles. This study sought to determine any difference in treatment outcomes between patients treated with either 1 or 2 cycles of concurrent MMC. Methods: 217 consecutive patients were treated definitively with CRT from 2003 to 2012 in an integrated health system. All patients received radiotherapy at a single regional facility. Concurrent chemotherapy regimen depended on the referring provider’s practice, and consisted of 2 cycles 5-FU (1,000mg/m2/day on days 1-4 and 29-32), along with MMC (10mg/m2), given on either day 1 alone (n=154), or days 1 and 29 (n=63). Outcomes were progression-free (PFS), cancer-specific (CSS), overall (OS), and colostomy-free survival (CFS), as well as acute toxicity criteria. Toxicity scored using CTCAE version 4. Survival analysis was via Kaplan-Meier method, and multivariate Cox proportional hazards modeling was performed. Results: Median age: 60 years. 70% female. T3-T4: 52%. 40% node-positive (N1: 7%, N2: 17%, N3: 16%). Median follow-up: 26 months. At last follow-up, PFS was 79%, CSS was 87%, OS was 81%, and CFS was 88% for the entire cohort. There were no differences in clinical/treatment factors between patients who received 1 cycle MMC (MMC1) vs 2 cycles (MMC2). There was no difference in PFS (HR 0.92, 95% CI 0.41-2.08), CSS (HR 0.36, 95% CI 0.08-1.62), OS (HR 0.73, 95% CI 0.27-2), or CFS (HR 0.91, 95% CI 0.31-2.67) between the MMC1 and MMC2 groups. On multivariate analysis, stage and male gender were predictive of worse PFS, CSS, OS, and CFS. Acute grade ≥2 toxicities for the MMC2 vs MMC1 group were: Skin: 97% vs 84% (p=0.006); Heme: 89% vs 73% (p=0.01); Leukopenia: 86% vs 68% (p=0.01); Neutropenia: 71% vs 53% (p=0.02). There were 3 treatment related deaths, all in the MMC2 group. Conclusions: This study provides evidence that MMC1 results in similar outcomes to MMC2 in patients with anal cancer treated with definitive CRT, with less acute treatment-related toxicity. Randomized trials comparing these 2 regimens could be considered.

Squamous cell carcinoma antigen as a marker for squamous cell carcinoma of the anal canal.

1988 ◽  
Vol 6 (5) ◽  
pp. 782-785 ◽  
Author(s):  
N J Petrelli ◽  
N Shaw ◽  
A Bhargava ◽  
J Daufeldt ◽  
L Herrera ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Anal Canal ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Squamous Cell Carcinoma Antigen ◽  
Serum Samples ◽  
False Negatives ◽  
Progression Of Disease ◽  
Scc Antigen

Twenty-one patients with documented squamous cell carcinoma (SCC) of the anal canal underwent prospective serial collection of 101 serum samples for radioimmunoassay of SCC antigen to evaluate regression or progression of disease. Eighteen presented with primary SCC of the anal canal, two with metastatic disease, and one with a recurrence in the perineum. Median follow-up was 18 months. Thirteen of 22 serum samples were true-positives, and nine of 22 were false-negatives. Four of 79 serum samples were false-positives and 75 of 79 were true-negatives. The sensitivity of this test is 59% and the specificity is 95%, with the accuracy of a positive test being 76%.

Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 4060-4060 ◽  
Author(s):  
Cathy Eng ◽  
Jane Rogers ◽  
George J. Chang ◽  
Y. Nancy You ◽  
Prajnan Das ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Anal Canal ◽  
Cell Carcinoma ◽  
Metastatic Disease ◽  
Squamous Cell ◽  
First Line ◽  
Curative Intent ◽  
Metastatic Squamous Cell Carcinoma ◽  
Line Chemotherapy

4060 Background: Metastatic squamous cell carcinoma (SCCA) of the anal canal is an uncommon malignancy with no standard approach. The reported median overall survival (OS) is 9-12 months (M) following 5-FU + cisplatin (FC)-based therapy. The aim of this study is to evaluate first-line chemotherapy approaches in this patient (pt) population. Methods: A retrospective analysis was conducted of 428 pts with metastatic SCCA of the anal canal identified from the MDACC tumor registry between 1/1/2000 - 5/31/2011. Electronic medical records were reviewed for histology, date of diagnosis and/or recurrence, site of metastasis, type of therapy provided, response rate (RR), progression-free survival (PFS), OS, and lines of salvage therapy. All eligible pts were required to be treatment-naïve for metastatic disease and have radiographic imaging at MDACC. Waiver of informed consent was obtained. Results: 99 pts fulfilled all criteria; 10 were lost to follow-up; 12 did not initiate chemotherapy. 77 pts were evaluable; M: F = 20:57; median age = 55 years (range: 37 - 82); HIV(+) = 5% (4/77); prior chemoXRT with curative intent: 70% (54/77), complete response (CR): 87% (47/54), median time to development of metastatic disease =17M. 29% (22/77) presented with metastatic disease. Sites of disease included distant lymph nodes (41%); liver (45 %); lung (25%); bone (15%); and brain (8%). The median follow up was 37M. 73% (56/77) of patients were treated with platinum-based therapy; 51% (n=39) received FC and 22% (n= 17) received carboplatin + paclitaxel (CP). The median PFS was 6M; FC trended better than CP for PFS (7M vs. 5M, p<0.067). The overall median OS = 29M. 40% (31/77) of pts received neoadjuvant first-line therapy followed by metastasectomy (68%), XRT (26%), or both (6%); resulting in a median OS = 35M. Conclusions: Metastatic SCCA of the anal canal is a malignancy in which 5-FU+cisplatin is a commonly used regimen. Our analysis suggests FC results in improved PFS over CP but is underpowered supporting further analysis. The short median PFS with front-line chemotherapy, and yet longer OS reflects the challenges in treating this patient population and the importance of multidisciplinary management in select cases.

scholarly journals Oral findings during follow-up of nasopharyngeal squamous cell carcinoma treatment: A case report

2021 ◽  
Vol 9 ◽  
pp. 2050313X2110330
Author(s):  
Atsushi Musha ◽  
Nobuteru Kubo ◽  
Naoko Okano ◽  
Hidemasa Kawamura ◽  
Yuhei Miyasaka ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Concurrent Chemoradiotherapy ◽  
Nasopharyngeal Cancer ◽  
Inflammatory Conditions ◽  
Positron Emission ◽  
History Of ◽  
Oral Area

A 50-year-old woman with a long history of nasopharyngeal cancer (T2N2M0, squamous cell carcinoma) underwent chemoradiotherapy and surgery. In the past, to prevent tumor recurrence or metastasis, she underwent concurrent chemoradiotherapy or neck dissection. However, during a follow-up 10 years after the surgery, intense F-18 fluorodeoxyglucose uptake was detected in the oral area (SUVmax 6.0). A biopsy of the area with F-18 fluorodeoxyglucose uptake revealed pathological inflammation. Radiography showed the presence of a wisdom tooth, located at the F-18 fluorodeoxyglucose accumulation site, and pericoronitis of this tooth was detected. Our findings indicate the importance of considering the effect of inflammatory conditions, such as periodontal disease, in using F-18 fluorodeoxyglucose positron emission tomography/computed tomography during follow-up after head and neck cancer treatment.

scholarly journals Squamous cell carcinoma of the scrotum in HIV: two case reports

2021 ◽  
Vol 27 (1) ◽  
Author(s):  
Jeff John ◽  
Ken Kesner ◽  
John Lazarus
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Case Reports ◽  
Treatment Options ◽  
Punch Biopsy ◽  
Delayed Treatment ◽  
Clinical Presentations ◽  
T1 N0 M0

Abstract Background Squamous cell carcinoma (SCC) of the scrotum was the first malignancy known to be associated with exposure to an occupational carcinogen—in this case, soot trapped in the breeches of chimney sweeps. Better civil rules and regulations and the replacement of hearths with other forms of heating have rendered SCC of the scrotum a rarity. We report two cases of scrotal SCC with vastly differing clinical presentations and management. Case presentation Case 1 had T1 N0 M0 disease and presented with a small (< 2 cm), innocuous-looking, non-healing ulcer of eight years duration. A punch biopsy revealed a superficially invasive SCC confirmed on immunohistochemical profiling. A wide local excision of the lesion was subsequently performed. Follow-up at three years showed no signs of recurrence. Case 2 presented with T4 N1 M1 disease and rapidly progressing locally destructive mass. A punch biopsy of the scrotal lesion confirmed invasive moderately differentiated focally keratinising SCC. The metastatic evaluation confirmed the presence of metastatic, extensive para-aortic lymphadenopathy. He was managed with cisplatin-based chemoradiotherapy. Conclusion Early detection and management of patients with SCC of the scrotum are essential. If the diagnosis is delayed, treatment options become limited, and the prognosis is poor. Notwithstanding the rarity of this disease, multicentre trials are needed to provide more precise guidelines as to the optimal management of these patients.

Sign in / Sign up

Export Citation Format

Share Document